Bayer expands ophthalmology pipeline with acquisiton of Perfuse Therapeutics; Viridian announces new phase 3 data for its investigational subcutaneous injection for chronic thyroid eye disease; and Steven Dell, MD discusses the impact of declining reimbursement could on ophthalmic practices. Learn more about your ad choices. Visit megaphone.fm/adchoices
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.
Listen to This Episode
More from Eyewire News: The Podcast
Tecnis PureSee IOL Fully Launched in the US
Study Examines Semaglutide and Wet AMD Risk
Oculis Announces Phase 3 Results for DME Eye Drops
Outlook Wins Appeal for Wet AMD Drug Candidate Lytenava
Get summaries like this every morning.
Free AI-powered recaps of Eyewire News: The Podcast and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.